ArticleAdvances in experimental medicine and biology2021
Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.
Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Applications of Nanobiotechnology in Medicine.Life (Basel, Switzerland) · 2026Review
- Potentiating Cancer Immune TherapyFrontiers in cell and developmental biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Up until now, surgery, radiation, and chemotherapy remain the conventional methods used in cancer treatment. However, these treatments are widely associated with severe side effects due to toxicity on normal cells. Consequently, there is an urgent need for novel therapeutic approaches that are able to effectively and selectively target tumor cells without any adverse effects on normal cells. Among the new approaches, cancer immunotherapy seems promising in the fight against tumors thanks to its prolonged efficacy and lower toxicity compared to the traditional treatments.Research studies suggested that both adjuvants and antigens are essential to induce optimal anti-tumor immunity. Among the different delivery strategies, nanotechnology offers several advantages for the design of cancer vaccines. Indeed, nanocarriers can protect the encapsulated antigens and/or adjuvant from enzymatic degradation, sustain and control the release for the entrapped cargo, and enhance the immune responses.Several studies reported that different physical characteristics of nanoparticles affect their uptake in cells and the potential to induce cellular responses. Among them, particle size and surface chemistry resulted the most influent.Clinical trials and recent research papers on the use of nanotechnology in cancer immunotherapy support the idea that this strategy could be successful as weapon against cancer in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.